Between 2019 and 2023, the market grew at a CAGR of 9%, driven by the rising health-consciousness of consumers, particularly millennial and Gen-Z parents. As precision nutrition technologies advance, ...
Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Read More on PLRX: Pliant Therapeutics NewsMORE Related Stocks ...
From the end of November Market data will no longer be displayed here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback